Signaturefd LLC Sells 7,417 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Signaturefd LLC decreased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 91.5% in the fourth quarter, Holdings Channel reports. The firm owned 690 shares of the biotechnology company’s stock after selling 7,417 shares during the quarter. Signaturefd LLC’s holdings in Sarepta Therapeutics were worth $84,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in SRPT. Wellington Management Group LLP increased its position in shares of Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Sarepta Therapeutics during the third quarter worth approximately $79,425,000. Janus Henderson Group PLC raised its stake in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares during the last quarter. Soros Fund Management LLC acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter worth approximately $25,800,000. Finally, Swedbank AB bought a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $16,706,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Up 3.0 %

Shares of NASDAQ SRPT opened at $76.33 on Tuesday. The company’s fifty day moving average is $106.35 and its 200-day moving average is $117.47. The stock has a market cap of $7.41 billion, a price-to-earnings ratio of 61.06 and a beta of 0.79. Sarepta Therapeutics, Inc. has a twelve month low of $73.05 and a twelve month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Royal Bank of Canada reduced their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Finally, Scotiabank lowered their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $167.41.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.